AMRX vs. CORT

In the year-to-date period, AMRX achieves a -1.14% return, which is significantly lower than CORT's 26.10% return. Over the past 10 years, AMRX has underperformed CORT with an annualized return of -15.21%, while CORT has yielded a comparatively higher 34.15% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Amneal Pharmaceuticals, Inc. (AMRX) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current AMRX Sharpe Ratio is 0.94, which is lower than the CORT Sharpe Ratio of 3.75. The chart below compares the historical Sharpe Ratios of AMRX and CORT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither AMRX nor CORT has paid dividends to shareholders.

The maximum AMRX drawdown since its inception was -97.52%, roughly equal to the maximum CORT drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for AMRX and CORT. For additional features, visit the drawdowns tool.

The current volatility for Amneal Pharmaceuticals, Inc. (AMRX) is 7.44%, while Corcept Therapeutics Incorporated (CORT) has a volatility of 21.04%. This indicates that AMRX experiences smaller price fluctuations and is considered to be less risky than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Amneal Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.